IVT PCV-25 / Inventprise - LARVOL DELTA

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=421 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Infectious Disease • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=420 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=420 | Not yet recruiting | Sponsor: Inventprise Inc.

New P2 trial • Infectious Disease • Pneumococcal Infections

PUTATIVE NOVEL SEROTYPES IN SEROGROUP 33 (ISPPD 2024) - "Background: Serotype 33F, a well-recognized invasive pneumococcal serotype is included in the higher valent pneumococcal conjugate vaccines (PCV) like PCV15, PCV20, PCV24, and IVT-25... While the prevalence of newly described serotype 33E is low within the GPS database, we identified four putative novel serotypes in serogroup 33 that warrant further characterization."

Infectious Disease • Pneumococcal Infections

GENOMIC CHARACTERISATION OF INVASIVE STREPTOCOCCUS PNEUMONIAE IN CHILDREN IN SLOVENIA (ISPPD 2024) - "In the post-PCV13 population, higher-valent PCV15, PCV20, PCV24 and IVT-25 will increase serotype coverage to 47.3% (44/93), 59.1% (55/93), 60.2% (56/93), 74.2% (69/93), respectively. In Slovenia, proportional decreases in vaccine serotypes among IPD cases in children after the introduction of PCV10/PCV13 was observed. Further surveillance is needed to confirm the emerging serotypes."

Clinical • Infectious Disease • Pneumococcal Infections • Pneumonia

GENOMIC CHARACTERISATION OF STREPTOCOCCUS PNEUMONIAE POPULATION CAUSING INVASIVE DISEASE IN LEBANON (ISPPD 2024) - "Higher valency vaccines such as PCV24 (68%; 56/82) and IVT25 would offer the highest serotype coverage in the PCV13 period. Vaccine effectiveness was demonstrated by the change in pneumococcal serotypes post-PCV13 introduction."

Clinical • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Septic Shock

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P2 | N=220 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P2 | N=220 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P2 | N=220 | Not yet recruiting | Sponsor: Inventprise Inc.

New P2 trial • Infectious Disease • Pneumococcal Infections

IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Inventprise Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | N=520 ➔ 65 | Trial completion date: Feb 2025 ➔ Jul 2023 | Trial primary completion date: Sep 2024 ➔ Jul 2023

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P1/2 | N=520 | Not yet recruiting | Sponsor: Inventprise Inc.

New P1/2 trial • Infectious Disease • Pneumococcal Infections